Andropause : Supporting Literature

J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53

Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group.

Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N.
Department of Medicine, Harbor-University of California-Los Angeles Medical Center and Research and Education Institute, Torrance 90509, USA.

Click here to access the PubMed abstract

The following study concluded that replacing testosterone in hypogonadal men increases bone mineral density of the spine and hip, fat-free mass, prostate volume, erythropoiesis, energy, and sexual function. The full effect of testosterone on bone mineral density took 24 months, but the full effects on the other tissues took only 3-6 months.

J Clin Endocrinol Metab 2000 Aug;85(8):2670-7

Effects of testosterone replacement in hypogonadal men.

Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL.
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Click here to access the PubMed abstract

Am J Med 2001 May;110(7):563-72

Hypogonadism and androgen replacement therapy in elderly men.

Basaria S, Dobs AS.
Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Click here to access the PubMed abstract

Drugs Aging 1999 Aug;15(2):131-42

Risks versus benefits of testosterone therapy in elderly men.

Basaria S, Dobs AS.
Division of Endocrinology and Metabolism, Johns Hopkins University, Baltimore, Maryland 21287, USA.

Click here to access the PubMed abstract

The findings below suggest that low levels of testosterone and SHBG play some role in the development of insulin resistance and subsequent type 2 diabetes.

Diabetes Care 2000 Apr;23(4):490-4

Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study.

Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB.New England Research Institutes, Watertown, Massachusetts, USA.

Click here to access the PubMed abstract

Manifestations of testosterone deficiency have included depression, anxiety, irritability, insomnia, weakness, diminished libido, impotence, poor memory, reduced muscle and bone mass, and diminished sexual body hair. Although testosterone levels decline with age, there is great interindividual variability.

Am J Psychiatry 1998 Oct;155(10):1310-8

Age-associated testosterone decline in men: clinical issues for psychiatry.

Sternbach H.
Department of Psychiatry, UCLA-Neuropsychiatric Institute, Los Angeles, USA.

Click here to access the PubMed abstract

Massive obesity in males is associated with decreased total and free testosterone levels as well as elevated estradiol levels.

Med Hypotheses 1999 Jan;52(1):49-51

The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt-a major factor in the genesis of morbid obesity.

Cohen PG.

Click here to access the PubMed abstract

These results suggest that testosterone treatment might improve depressed mood in older men who have low levels of bioavailable testosterone.

J Clin Endocrinol Metab 1999 Feb;84(2):573-7

Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study.

Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D.

Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093-0607

Click here to access the PubMed abstract

The following results suggest that until the age of 60 years, the mean serum level of DHEAS is lower in patients with ED than in healthy volunteers.

Urology 2000 May;55(5):755-8

Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction.

Reiter WJ, Pycha A, Schatzl G, Klingler HC, Mark I, Auterith A, Marberger M.

Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with lower dose

Forty consecutive patients with erectile dysfunction (mean age was 55 years) for more than three months were included in this study. Sixty-five percent of patients (13/20) who received sublingual sildenafil achieved satisfying erections and coitus, whereas the rate was 15% in the placebo group (3/20). The mean onset of action with sublingual sildenafil was 15.5 minutes and lasted for an average of 40 minutes. Minimal headaches, sweating and flushing were noted as the side-effects. The conclusion: “20 mg sublingual sildenafil is safe and effective in the treatment of erectile dysfunction. Sublingual administration has some advantages as it is not effected by food ingestion and quickly appears in the circulation. These advantages provide a faster onset of action with a lower dose when compared to oral sildenafil. Sublingual use of sildenafil may be more cost-effective and possibly provides a more predictable onset of action.”

Int J Urol. 2004 Nov;11(11):989-92

Click here to access the PubMed abstract of this article.

The International Journal of Pharmaceutical Compounding [March/April 2007;11(2):121] reported a formula for Sildenafil 20mg Troches (flavored) with a recommended beyond-use date of 180 days.